Allergan Plc Acquires RetroSense Therapeutics for $60,000,000
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=265a57a5-75bf-474d-8f14-cb009ca07fff
Date 9/6/2016
Company Name RetroSense Therapeutics
Mailing Address 330 East Liberty Street LL Ann Arbor, MI 48104 USA
Company Description Led by a team of seasoned veterans, RetroSense Therapeutics was founded in 2009 to develop a novel gene therapy approach to vision restoration.
M&A Terms Under the terms of the transaction, Allergan has paid RetroSense a $60 million upfront payment, and has agreed to potential regulatory and commercialization milestone payments related to its lead development program, RST-001, a novel gene therapy for the potential treatment of Retinitis Pigmentosa (RP).